

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Lubiprostone

October 22, 2025

Therapeutic category

Purgatives and clysters

Non-proprietary name

Lubiprostone

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS (N/A)	11. ADVERSE REACTIONS <u>11.1 Clinically Significant Adverse Reactions</u> <u>Anaphylaxis</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.